Effect of nicotine vapour inhalation on the relief of tobacco withdrawal symptoms

E. Lunell, L. Molander, K. O. Fagerström, S. J. Leischow

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Fifteen subjects participated in a randomised, placebo-controlled cross-over study to assess the effect of a nicotine vapour inhaler on craving and other withdrawal symptoms during a two-day smoking-free period. Craving and withdrawal symptoms were rated nine times over the two-day period on 10 cm visual analogue scales. Plasma nicotine concentrations in the afternoon of each study day were determined. The results show that active treatment was significantly superior to placebo in decreasing craving and other withdrawal symptom scores. No difference was found between two inhalation techniques, one with shallow, frequent inhalations (buccal technique), and the other with deep inhalations (pulmonary technique). The average number of active nicotine vapour inhalers and placebo inhalers used during the two-day sessions was 12 and 11, respectively. Afternoon plasma nicotine levels of approximately 7 ng/ml were obtained with both inhalation techniques. A strong correlation was found between the afternoon plasma nicotine levels and craving, a high nicotine level being associated with a low craving score. The study has provided information about how to use the nicotine vapour inhaler that could have important implications if it were to be approved for the treatment of tobacco dependence. The use of withdrawal symptom reduction as a surrogate endpoint is discussed.

Original languageEnglish (US)
Pages (from-to)235-240
Number of pages6
JournalEuropean Journal of Clinical Pharmacology
Volume48
Issue number3-4
DOIs
StatePublished - Jul 1 1995

Fingerprint

Substance Withdrawal Syndrome
Nicotine
Inhalation
Tobacco
Nebulizers and Vaporizers
Placebos
Tobacco Use Disorder
Cheek
Visual Analog Scale
Cross-Over Studies
Biomarkers
Smoking
Craving
Lung
Therapeutics

Keywords

  • craving
  • inhalation
  • Nicotine
  • plasma concentrations
  • smoking cessation
  • vapour inhaler
  • withdrawal symptoms

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Cite this

Effect of nicotine vapour inhalation on the relief of tobacco withdrawal symptoms. / Lunell, E.; Molander, L.; Fagerström, K. O.; Leischow, S. J.

In: European Journal of Clinical Pharmacology, Vol. 48, No. 3-4, 01.07.1995, p. 235-240.

Research output: Contribution to journalArticle

Lunell, E. ; Molander, L. ; Fagerström, K. O. ; Leischow, S. J. / Effect of nicotine vapour inhalation on the relief of tobacco withdrawal symptoms. In: European Journal of Clinical Pharmacology. 1995 ; Vol. 48, No. 3-4. pp. 235-240.
@article{1f152522d29d4b1d83a4871249157852,
title = "Effect of nicotine vapour inhalation on the relief of tobacco withdrawal symptoms",
abstract = "Fifteen subjects participated in a randomised, placebo-controlled cross-over study to assess the effect of a nicotine vapour inhaler on craving and other withdrawal symptoms during a two-day smoking-free period. Craving and withdrawal symptoms were rated nine times over the two-day period on 10 cm visual analogue scales. Plasma nicotine concentrations in the afternoon of each study day were determined. The results show that active treatment was significantly superior to placebo in decreasing craving and other withdrawal symptom scores. No difference was found between two inhalation techniques, one with shallow, frequent inhalations (buccal technique), and the other with deep inhalations (pulmonary technique). The average number of active nicotine vapour inhalers and placebo inhalers used during the two-day sessions was 12 and 11, respectively. Afternoon plasma nicotine levels of approximately 7 ng/ml were obtained with both inhalation techniques. A strong correlation was found between the afternoon plasma nicotine levels and craving, a high nicotine level being associated with a low craving score. The study has provided information about how to use the nicotine vapour inhaler that could have important implications if it were to be approved for the treatment of tobacco dependence. The use of withdrawal symptom reduction as a surrogate endpoint is discussed.",
keywords = "craving, inhalation, Nicotine, plasma concentrations, smoking cessation, vapour inhaler, withdrawal symptoms",
author = "E. Lunell and L. Molander and Fagerstr{\"o}m, {K. O.} and Leischow, {S. J.}",
year = "1995",
month = "7",
day = "1",
doi = "10.1007/BF00198304",
language = "English (US)",
volume = "48",
pages = "235--240",
journal = "European Journal of Clinical Pharmacology",
issn = "0031-6970",
publisher = "Springer Verlag",
number = "3-4",

}

TY - JOUR

T1 - Effect of nicotine vapour inhalation on the relief of tobacco withdrawal symptoms

AU - Lunell, E.

AU - Molander, L.

AU - Fagerström, K. O.

AU - Leischow, S. J.

PY - 1995/7/1

Y1 - 1995/7/1

N2 - Fifteen subjects participated in a randomised, placebo-controlled cross-over study to assess the effect of a nicotine vapour inhaler on craving and other withdrawal symptoms during a two-day smoking-free period. Craving and withdrawal symptoms were rated nine times over the two-day period on 10 cm visual analogue scales. Plasma nicotine concentrations in the afternoon of each study day were determined. The results show that active treatment was significantly superior to placebo in decreasing craving and other withdrawal symptom scores. No difference was found between two inhalation techniques, one with shallow, frequent inhalations (buccal technique), and the other with deep inhalations (pulmonary technique). The average number of active nicotine vapour inhalers and placebo inhalers used during the two-day sessions was 12 and 11, respectively. Afternoon plasma nicotine levels of approximately 7 ng/ml were obtained with both inhalation techniques. A strong correlation was found between the afternoon plasma nicotine levels and craving, a high nicotine level being associated with a low craving score. The study has provided information about how to use the nicotine vapour inhaler that could have important implications if it were to be approved for the treatment of tobacco dependence. The use of withdrawal symptom reduction as a surrogate endpoint is discussed.

AB - Fifteen subjects participated in a randomised, placebo-controlled cross-over study to assess the effect of a nicotine vapour inhaler on craving and other withdrawal symptoms during a two-day smoking-free period. Craving and withdrawal symptoms were rated nine times over the two-day period on 10 cm visual analogue scales. Plasma nicotine concentrations in the afternoon of each study day were determined. The results show that active treatment was significantly superior to placebo in decreasing craving and other withdrawal symptom scores. No difference was found between two inhalation techniques, one with shallow, frequent inhalations (buccal technique), and the other with deep inhalations (pulmonary technique). The average number of active nicotine vapour inhalers and placebo inhalers used during the two-day sessions was 12 and 11, respectively. Afternoon plasma nicotine levels of approximately 7 ng/ml were obtained with both inhalation techniques. A strong correlation was found between the afternoon plasma nicotine levels and craving, a high nicotine level being associated with a low craving score. The study has provided information about how to use the nicotine vapour inhaler that could have important implications if it were to be approved for the treatment of tobacco dependence. The use of withdrawal symptom reduction as a surrogate endpoint is discussed.

KW - craving

KW - inhalation

KW - Nicotine

KW - plasma concentrations

KW - smoking cessation

KW - vapour inhaler

KW - withdrawal symptoms

UR - http://www.scopus.com/inward/record.url?scp=0029116977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029116977&partnerID=8YFLogxK

U2 - 10.1007/BF00198304

DO - 10.1007/BF00198304

M3 - Article

C2 - 7589047

AN - SCOPUS:0029116977

VL - 48

SP - 235

EP - 240

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

IS - 3-4

ER -